Analysis for COR

📈 Growth & Financial Trajectory

Over the 8 quarters, COR's revenue progressed from about $74.2B in 2024 Q3 to a peak around $85.9B in 2025 Q1, then eased to about $78.4B in 2026 Q2. Net income climbed from a small positive in 2024 Q3 to about $1.63B in 2026 Q2, supported by favorable tax/non-operating items in Q2 2026, signaling a meaningful earnings improvement despite quarterly volatility.

The path shows an overall upshift in earnings power with revenue oscillating but staying well above the 2024 trough, reflecting improved scale and mix.

💰 Margins & Cash Flow

Gross margins have trended around 4% on revenue, with operating margins hovering near 1–2% across periods. The mix and costs drive a modest operating leverage, though net income expanded meaningfully in late-2024 through 2026, aided by tax/one-off effects in the latest quarter. Cash flow: operating cash flow was generally positive (notably Q4 2025 and 2026 Q2), investing cash flow was typically negative, and financing activity varied; overall cash movement shows resilience in later quarters.

🛡️ Balance Sheet & Liquidity

Total assets sit in the low-to-mid $80B range; liabilities exceed equity with current liabilities around the mid $50B and long-term debt around $12B in the latest quarter. The current ratio sits near 1.0, suggesting modest near-term liquidity. Leverage remains high, but steady operating cash flow supports debt service and liquidity.

⚠️ Key Drivers & Risks

• Drivers: Pharmaceutical distribution demand; Healthcare supply-chain resilience
• Risks: Earnings volatility from non-operating items/tax effects; Balance-sheet leverage and cyclicality in healthcare logistics